Roth Capital Starts Fate Therapeutics (FATE) at Buy

September 22, 2016 8:16 AM EDT
Get Alerts FATE Hot Sheet
Price: $2.20 -2.22%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 7
Trade FATE Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Roth Capital initiated coverage on Fate Therapeutics (NASDAQ: FATE) with a Buy rating and a price target of $8.00.

For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.

Shares of Fate Therapeutics closed at $3.18 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Related Entities

Roth Capital

Add Your Comment